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Although amiodarone was initially introduced 
as an antianginal drug, its anti-arrhythmic proper-
ties were soon appreciated and over the last four 
decades it has been used clinically in the manage-
ment of both atrial fibrillation (AF) and ventricular 
arrhythmias. Amiodarone has been shown to be 
superior to both sotalol and propafenone in the 
maintenance of sinus rhythm in patients with at 
least one episode of AF [1]. Although some studies 
have shown some potential benefit of amiodarone 
in the management of patients with potentially life 
threatening ventricular arrhythmias, this has not 
been shown to be a consistent finding [2, 3].
The predominant mode of action is class III 
by inhibiting the IKr and IKs channels resulting 
in a prolongation of myocardial repolarization 
homogeneously. It also exhibits class I effects by 
blocking the sodium channels reducing the con-
duction velocity, class II effects by blocking the 
beta-adrenergic receptors and class IV effects by 
inhibition of the L type calcium channel.
Despite the fact that amiodarone is not and 
never has been approved by the Food and Drug 
Administration for the management of AF, it is the 
most commonly used antiarrhythmic drug used 
for this purpose [4]. This may be based on the fact 
that the drug appears to be effective with minimal 
cardiac contraindications. Unlike several of its com-
petitors, it can be used in patients with impaired 
left ventricular function as well as coronary artery 
disease. Although prolongation of the QT interval is 
commonly seen this results in torsades de pointes 
in less than 0.5% of cases [5, 6]. In fact, the most 
common cardiac side effect is sinus bradycardia [7].
The major Achilles heel of amiodarone therapy 
appears to be related to its non-cardiac side ef-
fects as a result of tissue penetration and organ 
toxicity related to the iodine moiety. The list of 
potential side effects is exhaustive and includes 
thyroid dysfunction, lung toxicity, inflammatory 
hepatotoxicity, skin reactions, retinal deposits and 
pancreatitis. It is therefore good clinical practice 
to carefully evaluate the potential side effects and 
discuss these in detail with the patient as well as 
draw up a monitoring strategy prior to commenc-
ing amiodarone.
The manuscript by Qin et al. [8] was a ret-
rospective analysis of patients with structurally 
normal hearts prescribed anti arrhythmic drugs for 
the management of AF. Approximately one fifth of 
these patients were prescribed amiodarone. The 
remainder were prescribed flecainide, propafenone, 
sotalol, dofetilide or dronedarone.
Like many studies of this nature, there may 
be some selection bias and it is noted that pa-
tients prescribed amiodarone tended to be more 
elderly with a higher Charlson comorbidity index. 
Although propensity matching may help to bal-
ance significant differences, caution must still be 
exercised as several additional differences may still 
exist which are not adjusted for and which may have 
been part of the decision process for the physicians 
when prescribing the anti arrhythmic in the first 
place. The most important factor of all which was 
taken into account was to exclude patients with 
structural heart disease including congestive car-
diac failure, coronary artery disease, severe left 
ventricular hypertrophy and severe valvular heart 
disease. This helped to maintain a relatively even 
playing field in terms of the ability to use any of the 
above mentioned antiarrhythmic drugs. What the 
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authors found was certainly interesting. Firstly and 
importantly, primary care physicians were more 
likely to prescribe amiodarone that cardiologists 
or electrophysiologists. This may reflect a lack of 
clinical experience with alternative antiarrhyth-
mic agents in this group of physicians. Given the 
relative cardiac safety of amiodarone, this may be 
considered an easier therapeutic decision. Car-
diologists and electrophysiologists may be more 
selective in terms of the types of patients who are 
commenced on amiodarone. This may require fur-
ther evaluation and education. The fact that there 
was no significant difference in AF recurrence 
may reflect the way this information was collected 
and there is probably insufficient data to draw any 
further conclusions.
As it would be expected, there was no differ-
ence in cardiac deaths between the two groups 
of patients. There was, however, a higher rate of 
non-cardiac deaths in the group receiving amiodar-
one versus those receiving other anti arrhythmic 
agents. The non-cardiac causes included respira-
tory failure not related to interstitial lung disease, 
unspecified neoplasm, pulmonary embolism, de-
mentia, trauma, stroke and a perforated bowel. 
To the best of our knowledge, none of these are 
currently considered to be directly related to ami-
odarone and this may be a general reflection of the 
patients selected for therapy with amiodarone. De-
spite this, we strongly recommend that amiodarone 
should always be used with the utmost caution and 
that patients are closely monitored for any potential 
side effects. All current antiarrhythmic drugs have 
limited efficacy and multiple potential side effects, 
and we should continue to strive to develop more 
selective agents with minimal side effects.
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